Display options
Share it on

Clin Epidemiol. 2016 Oct 25;8:679-683. doi: 10.2147/CLEP.S99469. eCollection 2016.

Danish Registry of Childhood and Adolescent Diabetes.

Clinical epidemiology

Jannet Svensson, Charlotte Cerqueira, Per Kjærsgaard, Lene Lyngsøe, Niels Thomas Hertel, Mette Madsen, Henrik B Mortensen, Jesper Johannesen

Affiliations

  1. Pediatric and Adolescent Department, Copenhagen University Hospital, Herlev and Gentofte, Herlev.
  2. Registry Support Centre (East) - Epidemiology and Biostatistics, Research Centre for Prevention and Health, Capital Region of Denmark, Glostrup.
  3. Pediatric Department, County Hospital Herning, Herning.
  4. Pediatric and Adolescent Department, Nordsjællands Hospital, Hillerød.
  5. HC Andersen Childrens Hospital, Odense University Hospital, Odense.
  6. Pediatric Department, Aalborg University Hospital, Aalborg, Denmark.

PMID: 27822115 PMCID: PMC5094642 DOI: 10.2147/CLEP.S99469

Abstract

AIM: The aims of the Danish Registry of Childhood and Adolescent Diabetes (DanDiabKids) are to monitor and improve the quality of care for children and adolescents with diabetes in Denmark and to follow the incidence and prevalence of diabetes.

STUDY POPULATION: The study population consists of all children diagnosed with diabetes before the age of 15 years since 1996. Since 2015, every child followed up at a pediatric center (<18 years of age) will be included.

MAIN VARIABLES: The variables in the registry are the quality indicators, demographic variables, associated conditions, diabetes classification, family history of diabetes, growth parameters, self-care, and treatment variables. The quality indicators are selected based on international consensus of measures of good clinical practice. The indicators are metabolic control as assessed by HbA1c, blood pressure, albuminuria, retinopathy, neuropathy, number of severe hypoglycemic events, and hospitalization with ketoacidosis.

DESCRIPTIVE DATA: The number of children diagnosed with diabetes is increasing with ∼3% per year mainly for type 1 diabetes (ie, 296 new patients <15 years of age were diagnosed in 2014). The disease management has changed dramatically with more children treated intensively with multiple daily injections, insulin pumps, and increased number of self-monitored blood glucose values per day. These initiatives have resulted in a significant improvement in HbA1c over the years and a decrease in the number of children experiencing severe hypoglycemia, diabetic nephropathy, and retinopathy.

CONCLUSION: The systematic collection of data in DanDiabKids documents improved quality of care over the last 12 years, despite a substantial increase in the number of patients cared for by pediatric departments in Denmark, fulfilling the purpose of the registry.

Keywords: DanDiabkids; HbA1c; quality of care; severe hypoglycemia; treatment modalities

Conflict of interest statement

JS has Novo Nordisk shares and is a member of Bayer and Novo Nordisk advisory board. PK has received salary in a Novo Nordisk-sponsored register study on growth hormone treatment. NTH has received fee

References

  1. Pediatr Diabetes. 2009 Sep;10 Suppl 12:1-2 - PubMed
  2. Diabet Med. 2005 Nov;22(11):1566-73 - PubMed
  3. Pediatr Diabetes. 2015 Aug;16(5):354-60 - PubMed
  4. Pediatr Diabetes. 2015 Jun;16(4):256-62 - PubMed
  5. Diabet Med. 2003 Jul;20(7):568-74 - PubMed
  6. Pediatr Diabetes. 2014 Nov;15(7):469-76 - PubMed
  7. Pediatr Diabetes. 2009 Nov;10(7):461-7 - PubMed
  8. Pediatr Diabetes. 2014 Nov;15(7):519-27 - PubMed
  9. Pediatr Diabetes. 2016 Aug;17 (5):368-73 - PubMed
  10. Acta Diabetol. 2015 Jun;52(3):591-9 - PubMed
  11. Pediatr Diabetes. 2009 Jun;10(4):248-54 - PubMed
  12. Diabetes Res Clin Pract. 2015 Aug;109(2):279-86 - PubMed
  13. Pediatr Diabetes. 2015 Nov;16(7):504-9 - PubMed
  14. Diabetologia. 2013 May;56(5):995-1003 - PubMed

Publication Types